Radiolabeled antibodies in renal cell carcinoma. by Stillebroer, A.B. et al.
PDF hosted at the Radboud Repository of the Radboud University
Nijmegen
 
 
 
 
The following full text is a publisher's version.
 
 
For additional information about this publication click this link.
http://hdl.handle.net/2066/52852
 
 
 
Please be advised that this information was generated on 2017-12-06 and may be subject to
change.
Cancer Imaging (2007) 7, 179188
DOI: 10.1102/1470-7330.2007.0025
ARTICLE
Radiolabeled antibodies in renal cell carcinoma
Alexander B. Stillebroera,b, Egbert Oosterwijka, Wim J.G. Oyenb, Peter F.A. Muldersa and
Otto C. Boermanb
aDepartment of Urology and bDepartment of Nuclear Medicine, Radboud University Nijmegen Medical Centre,
Nijmegen, The Netherlands
Corresponding address: Alexander B. Stillebroer, MD, Radboud University Nijmegen Medical Centre,
Department of Urology - 659, PO Box 9101, 6500 HB Nijmegen, The Netherlands.
Email: a.stillebroer@uro.umcn.nl
Data accepted for publication 15 August 2007
Abstract
Renal cell carcinoma (RCC) is a radio- and chemotherapy resistant tumor, which has a very high morbidity and
mortality when metastasized. The current treatment options demonstrate limited efficacy and severe side-effects.
Therefore, there is a need for new therapeutic strategies for RCC. As for other malignancies, monoclonal antibodies
(mAbs) targeting tumor-associated antigens have been developed for RCC. One of these, mAb G250, targets the
MN/CAIX/G250 antigen, which is ubiquitously expressed in clear cell RCC (ccRCC). ccRCC is the most common
form of RCC with a prevalence of 80%. Expression of G250 in normal tissue is restricted to the gastrointestinal
mucosa and related structures, thereby making it a suitable candidate for targeting ccRCC. In several clinical
studies the efficient accumulation of mAb G250 in ccRCC has been demonstrated, resulting in high contrast
images. G250-imaging could prove to be a valuable tool in diagnosing metastases in patients with a G250-antigen
positive primary tumor and/or in the differential diagnosis of suspect kidney lesions. Furthermore, the therapeutic
efficacy of radiolabeled G250 has been investigated in a series of studies. Thus far, most efforts have been devoted to
G250 labeled with high doses of 131I. Other radionuclides which may enhance the therapeutic index of this radi-
olabeled mAb are currently under investigation. In our institution, an activity dose escalation study is currently
ongoing to investigate the therapeutic potential of 177Lu-labeled G250 in metastatic ccRCC patients. In this
review, the current status of the diagnostic and therapeutic properties of radiolabeled antibodies in RCC is described.
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Introduction
Renal cell carcinoma (RCC) is the most common malig-
nancy arising in the kidney. In the United States alone,
each year 39,000 people are diagnosed with RCC and
13,000 people die from the disease[1]. The classic triad of
Virchow (flank pain, hematuria and a palpable abdomi-
nal mass) is only seen in approximately 9% of newly
diagnosed patients[2]. This considerably complicates
the diagnosis, since the disease can present with a
broad array of (paraneoplastic) symptoms[3,4]. As a con-
sequence, 30% of patients will present with metastatic
disease, whereas of the other 70% treated by nephrect-
omy, 3040% will eventually relapse[1]. The 5-year sur-
vival rate for small (less than 7 cm) tumors limited to the
kidney (pT1 tumor) is more than 90%[5], but prognosis
for metastatic disease is bleak, with a median survival of
only 10 months[6]. RCC is known as a chemotherapy and
radiation resistant tumor[7,8]. Therefore, therapeutic stra-
tegies focus on immunotherapy, neoangiogenesis inhibi-
tors and other targeted approaches. In this review,
another approach using antibodies developed for target-
ing RCC is discussed and particularly their application in
the diagnosis and therapy of RCC.
Monoclonal antibodies
Since the first description of Ehrlich to specifically guide
cytotoxic therapy to cancer tissue[9], much has been
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debated on the feasibility of this approach. Development
of the hybridoma technique[10] allowed isolation of large
quantities of antibodies with predefined specificity.
With the identification of the tumor-associated target
antigens, real progress has been made on developing
treatment and/or diagnostic strategies using mAbs.
To date, no tumor specific antigen, i.e. an antigen
expressed on all tumor cells which is not expressed by
normal cells in the body, has been identified. Tumor-
associated antigens (TAA) have been identified for a
series of human tumor types[1115]. These are either dif-
ferentiation antigens, (transiently) expressed during orga-
nogenesis, or aberrantly expressed antigens, (transiently)
expressed elsewhere in non-related normal tissue(s).
Expression of antigen on the primary tumor or metasta-
ses is generally heterogeneous. For tumor targeting
with mAbs this is a suboptimal feature, since not all
cells can be targeted by the mAb. Heterogeneous expres-
sion between different tumor sites, varying degrees of
expression in tumor cells of the same tumor and temporal
modulation of TAA-expression are considered major
limitations of effective targeting of tumors with mAbs.
In addition to intratumoral heterogeneity of antigen
expression, other parameters have been defined that
may be equally important in hampering tumor targeting
with mAbs. These are: size of the tumor mass, the antigen
density, the fate of antigen/antibody complex, presence
of circulating antigen, mAb format, mAb dose, route of
administration and mAb circulating half-life[16]. These
parameters can differ from one tumor type to another.
Also, tumor physiology is an important factor in antigen
targeting by mAbs. Mab targeting is complicated by large
tumor blood vessels as well as impaired blood flow in the
tumor by elevated interstitial fluid pressure (IFP)[17].
High vascular density is not equivalent to high perfusion
rates in the tumor, which are required for optimal mAb
delivery. RCC has always been considered a highly vas-
cularized tumor by morphologic standards. However, in
comparison with normal kidney tissue RCC is poorly
perfused[17], thereby impeding adequate mAb delivery
to the tumor cells. These limitations of delivering the
mAb to tumor tissue have to be overcome in order to
develop a suitable mAb-based treatment strategy.
Several mechanisms to eradicate tumor cells by mAbs
are available: either via effector cells or complement
dependent cytotoxicity or through conjugation of the
mAb to toxins, drugs or radionuclides. Since antigen
expression within tumors is heterogeneous, antigen-nega-
tive tumor cells may evade tumor cell lysis by effector
cell- or complement-mediated cytotoxicity, which may
eventually lead to tumor recurrence. The same applies
to mAbs conjugated to toxins or drugs, since internaliza-
tion of a mAb conjugated to a toxin or drug is required to
mediate cell-killing[16].
Radiolabeling of antibodies was developed in 1950,
when Eisen observed that proteins could be labeled with
131I without altering their immunological specificity[18].
Besides 131I, other radionuclides (90Y, 177Lu, 186Re,
188Re and 67Cu) have since been investigated to induce
tumor cell death (see Table 1). The advantage of radiola-
beled antibodies is that the mAb does not have to bind to
every tumor cell to induce cytotoxicity, since the radio-
nuclides emit b-particles, which can be effective for up
to 50 or more cell diameters. This so-called crossfire
effect can thus overcome heterogeneity of antigen expres-
sion, as the radiation destroys the antigen-negative cells as
well. A disadvantage of this technique is the sensitivity of
normal organs to radiation, particularly the bone marrow.
The dose limiting toxicity of delivering high-dose radio-
immunotherapy (RIT), i.e. a radionuclide conjugated to
a tumor-associated mAb, is therefore generally
hematological.
Using the previously mentioned hybridoma technique
a wide array of mAbs against TAAs has been produced,
e.g. mAbs against carcino-embryonic antigen (CEA)
(mainly expressed in colorectal and medullary thyroid
carcinomas), MUC-1 (mainly ovarian and breast
cancer), TAG72 (mainly ovarian and colorectal
cancer), CD-20 (non-Hodgkins lymphoma (NHL)) and
G250-antigen (RCC). In various clinical trials safety and
efficacy of these newly developed mAbs labeled with var-
ious radionuclides have been investigated[11].
Radioimmunotherapy with mAbs targeting NHL have
Table 1 Radionuclides used in radioimmunotherapy of clear cell renal cell carcinoma
Radionuclide Half-life b-average
(keV)
g
(keV)
Maximum
range b-particles
in tissue (mm)
Advantages Disadvantages
131I 8.0 days 192 362 3.0 Easy labeling; inexpensive High radiation burden to personnel/
relatives; hospital admittance
required
186Re 90.7 h 362 137 5.1 Out-patient treatment
possible; ideal gamma for
imaging
Laborious labeling
90Y 64 h 935 None 12 High-energy beta-emission; pro-
longed tumor retention; out-
patient treatment possible
No imaging possible
177Lu 6.7 days 149 208 2.5 Prolonged tumor retention
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shown exciting results. These tumors are relatively radio-
sensitive and mAbs have good access to the tumor. The
effector cell, complement and apoptosis inducing cyto-
toxicity of the mAb give high intrinsic anti-tumor activity
as well. Extensive research has resulted in the first regis-
tered treatment with radiolabeled mAbs directed against
the surface antigen CD-20 expressed on B-cell NHL (90Y-
labeled anti-CD20 mAb Ibritumomab Tiuxetan
(Zevalin, Biogen Idec, Boston MA, USA and
Schering, Berlin, Germany) and 131I-labeled anti-CD20
mAb tositumomab (Bexxar, GSK, Philadelphia, PA,
USA).
In patients with solid tumors, therapeutic strategies
with radiolabeled mAbs have been less successful than
in patients with hematological malignancies. This is
partly due to the lower radiation sensitivity of solid
tumors. However, as mentioned previously, tumor-related
factors also play an important role. The most common
types of solid malignancies targeted in clinical trials with
RIT have been epithelial cancers, e.g. colorectal cancer,
ovarian cancer, medullary thyroid cancer, breast cancer,
prostate cancer and RCC. Results of these trials did not
result in registration of radiolabeled mAb preparations
for regular treatment of these cancer types. However,
patients entered in these trials often had bulky metastatic
disease and had been heavily pretreated with chemother-
apy and/or radiotherapy in most cases. Complete
responses to RIT have incidentally been reported.
Partial responses and stabilization of previously progres-
sive disease have been seen in few patients in most of
these trials[19].
Radiolabeled peptides in renal
cell carcinoma
Peptides have been used for radionuclide targeting of
tumors to overcome the difficulties in tumor targeting
with mAbs mentioned above. These peptides have a
high affinity for specific receptors that are expressed on
the tumor cell. Following binding to the receptor the
peptidereceptor complex is internalized, resulting in
intracellular retention. Tumor targeting peptides have
advantages over mAbs, as they diffuse rapidly in target
tissue and clear rapidly from the blood and from the non-
target tissues. Peptides are usually non-immunogenic and
generally have a low toxicity profile. Peptide receptor
radionuclide imaging (PRRI) and therapy (PRRT) are
now under investigation. To date, the somatostatin
(SST) analog 111In-labeled-octreotide (OctreoScan,
Mallinckrodt Tyco Healthcare, Petten,
The Netherlands) is the most successful radiopeptide
for tumor imaging and has been the first to be approved
for scintigraphic localization of primary and metastatic
neuro-endocrine tumors expressing SST2 and SST5
receptor subtypes[20]. Expression of these receptors was
found in 72% of RCC samples analyzed, irrespective of
histopathological subtype or grading of the tumor[21].
The use of [111In]octreotide has been evaluated in
patients with metastatic RCC. In this study, 68 RCC
metastases in 9 patients, confirmed by diagnostic CT
and/or X-ray images were evaluated. Forty (59%) of the
68 known sites were visualized[22]. Besides octreotide, a
new series of peptides is now being evaluated for target-
ing of solid tumors. Cholecystokinin (CCK) analogues,
vasoactive intestinal peptide (VIP), neuropeptide Y
(NPY), bombesin, glucagon-like peptide-1 (GLP-1) and
RGD peptides have shown promising preclinical tumor-
receptor targeting (for review see Reubi[23]).
The gastrointestinal peptide gastrin acts as a neuro-
transmitter in the brain and as a regulator of various
functions in the gastrointestinal tract[24]. It mediates its
actions via the CCK1 and CCK2 receptors
[25]. These
receptors are highly expressed in medullary thyroid car-
cinoma (MTC), enabling gastrin to visualize metastatic
MTC with very high sensitivity[26]. RCC however, does
not express these receptors and gastrin is therefore not
suitable for RCC imaging[23].
VIP, a member of the group of secretin-like peptides, is
an important neurotransmitter in the gut. Its actions are
mediated by specific G protein-coupled receptors that
can be internalized upon ligand binding[27]. Although
expression of the VIP receptors has been found on
nephroblastomas[28], expression on RCC has not been
determined.
NPY is a neurotransmitter that is predominantly
found in the central nervous system, where it functions
as a stimulator of feeding behavior and inhibition of
anxiety[29]. More recently, expression of NPY receptors
has been found on RCC and nephroblastomas, suggest-
ing a potential role for RCC targeting using radiolabeled
NPY[30].
Bombesin has a high and specific affinity for the gas-
trin releasing peptide receptor (GRP-R) and this receptor
stimulates proliferation of tumor growth in various tumor
types[31]. RCC has been found to have a high expression
of GRP-R[32]. Targeting of RCC was done using a bom-
besin analogue labeled with 177Lu. In this study, in vitro
autoradiography showed specific uptake of the radioli-
gand in five of the six RCC samples evaluated[33].
Recently, GLP-1 receptor expression in solid human
tumors has been evaluated extensively and systematically.
This study found no GLP-1 receptor expression in 20
RCC tissue samples analyzed, excluding GLP-1 receptor
as a target for in vivo RCC imaging or therapy[34].
RGD peptides contain the amino acid sequence Arg-
Gly-Asp that has high and specific affinity for the avb3
integrin[35]. This integrin is mainly expressed on prolifer-
ating endothelial cells, whereas it is not expressed on
quiescent endothelial cells[36]. In growing tumors a con-
tinuous formation of new blood vessels is required.
The avb3 integrin is considered a marker of angiogenesis
in tumors. In addition, avb3 integrin is also expressed on
various tumor cells including RCC. The expression of
avb3 has been found to increase with higher RCC
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tumor grades. Of the RCC metastases examined, 2 of 14
showed high expression of avb3, 8 of 14 showed weak
expression and 4 of 14 did not express the avb3 integ-
rin[37]. To date, RGD peptides have not been evaluated
for RCC imaging.
Monoclonal antibodies in renal
cell carcinoma
In RCC, several mAbs have been defined that are reac-
tive with RCC-associated antigens[3847]. Most of these
recognize kidney differentiation antigens expressed by
subsets of RCC. Cross-reactivity with non-kidney tissue
was seen in some of these mAbs, whereas others were
only expressed in kidney/RCC.
One of these mAbs, which showed relative high tumor-
to-blood ratios in mice with RCC xenografts is mAb
A6H[48,49]. This mAb recognizes an antigen common
to RCC, some lung and colon carcinomas, the proximal
renal tubules but no other normal tissues in vivo[50]. In a
clinical study, the imaging and RIT potential of this mAb
was examined[49]. Positive images were obtained in 5 of
15 patients. This low sensitivity was attributed to soluble
antigen binding by the mAb and the expression of anti-
gen in normal tissue, thereby not allowing the mAb to
bind to tumor tissue. This clinical finding of antigen
expression in normal tissue was not in line with the pre-
vious findings. After modification of the dosing regimen,
the detection rate of metastatic lesions increased, but the
number of detected lesions remained unsatisfactory. As a
result, the use of mAb A6H for diagnosis and treatment
of RCC was discontinued.
Discovery and use of G250:
from mG250 to cG250
G250, a mAb against a RCC-associated antigen has been
investigated extensively, because the antigen which this
mAb recognizes showed remarkable tissue distribution
and expression. The mAb G250 was obtained after
fusion of spleen cells from a mouse immunized with
fresh RCC homogenates. The antigen that mAb G250
targets has been designated in the literature as MN,
CA IX and G250. The term G250-antigen is used in
this review. Of the 47 primary RCC specimens initially
analyzed, 42 (89%) showed homogeneous G250-antigen
expression, whereas four tumors showed heterogeneous
expression and one tumor was G250-antigen-negative. Of
the eight metastases examined, G250-antigen expression
was homogeneous in five (62%), heterogeneous in two,
while one did not express the G250-antigen[43].
Expression in normal tissues has been evaluated exten-
sively and has been shown to be restricted to the (upper)
gastrointestinal mucosa (stomach, ileum, proximal and
middle colon) and gastrointestinal related structures
(intra- and extrahepatic biliary system, pancreas)[43,51,52].
Later studies showed an almost ubiquitous expression
(490%) of G250-antigen in clear cell RCC (ccRCC),
being the most prominent form of RCC (80% of
cases). G250-antigen expression in the different histolo-
gical subtypes of RCC was determined by RT-PCR and
immunohistochemistry. All the clear cell tumors dis-
played G250-antigen mRNA, but expression of G250-
antigen by oncocytomas, chromophobe or papillary
RCC was low or absent[5355]. These results directed
the scope of G250-mAb studies to clear cell type RCC.
An early or a first event in the clear cell RCC tumor-
igenic pathway is mutations leading to loss of Von Hippel
Lindau protein (pVHL) in 5075% of sporadic RCC. In
normoxic conditions pVHL is responsible for degrada-
tion of hypoxia inducible factor-1a (HIF-1a), which
thereby cannot bind to HIF-1b to form HIF-1. In hypoxic
conditions, however, degradation does not occur and
HIF-1 can cause the transcription of a number of
hypoxia-inducible genes. These include vascular endothe-
lial growth factor (VEGF), transforming growth factor-a
(TGFa), erythropoietin, G250-antigen and others.
Clearly, expression of these proteins is advantageous
for tumor growth. With the loss of functional pVHL in
RCC the hypoxia response pathway is also active,
thereby mimicking hypoxic conditions[56]. This muta-
tional loss of pVHL thus explains why G250-antigen is
almost invariably upregulated in ccRCC. G250-antigen is
also expressed in various other tumor types (e.g. cervix,
lung) under hypoxic conditions.
Various animal and ex vivo experiments have shown
the potential of the G250 mAb as a targeting modality
of RCC[5762]. Since G250-antigen is high and homoge-
neously expressed in RCC tissue, is restricted to a few
normal tissues and other tumors, and a low mAb dose is
needed to obtain antigen saturation, mAb G250 seemed a
suitable candidate for further investigation in clinical
studies.
Two clinical studies with radiolabeled murine G250
(mG250) have been completed. Imaging and biodistribu-
tion were studied in 16 patients receiving 370 MBq
131I-labeled mG250 at escalating protein dose levels
1 week prior to nephrectomy. After 34 days clear delin-
eation of tumors was seen in 12 patients, imaged with a
gamma camera. Ten of these tumors proved to be G250-
positive, whereas the other two showed less than 5%
G250-antigen expression. The four tumors that were
not visualized were non-clear cell RCC. After nephrect-
omy, tumor samples were shown to have high and focal
uptake of G250, up to 0.21 % injected dose/gram
(%ID/g). Tumor targeting was not the result of blood
pooling, as the blood volume marker 99mTc-labeled
human serum albumin showed significantly lower
tumor uptake than [131I]mG250 that had been adminis-
tered earlier. Therefore, this was indicative of true anti-
body targeting of the tumor by mG250[63]. As good
targeting of ccRCC by mG250 was seen in this study, a
phase I/II radioimmunotherapy (RIT) dose escalation
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study was performed by Divgi et al. Patients in this study
were treated with one high-activity-dose injection of
[131I]mG250. After reaching the maximum tolerated
dose (MTD), another 15 patients were enrolled and trea-
ted at the MTD to monitor any possible therapeutic
effects. In the phase I dose-escalation study, MTD was
defined at 3330 MBq/m2, due to hematological toxicity.
Transient hepatic toxicity occurred at dose levels of 1665
MBq/m2 and higher, but was not dose limiting. Fourteen
patients had grade 3 hepatic toxicity, that did not last for
more than 2 weeks. A total of 33 patients was treated,
18 in the dose-escalating part of the study and another
15 patients at the MTD (3330 MBq/m2), to evaluate
therapeutic efficacy. Of these 33 patients, 17 stabilized
for 3 months, after which patients received other treat-
ments, preventing further follow-up. Three patients
showed regression of some of their lesions, but no partial
or complete responses were noted[64].
The formation of human anti mouse antibodies
(HAMA) in all patients receiving mG250 prohibited
retreatment. Formation of immune complexes with
rapid clearance of the radiolabeled mAb to liver and
spleen would have occurred in the case of multiple
administrations, thereby limiting targeting of the mAb
to the tumor[64]. This, in combination with the high
potential of G250 as a targeting agent in the treatment
of metastasized RCC, led to the development of a chi-
meric form of G250 (cG250)[65]. This mAb is composed
of murine antigen-binding variable domains, that recog-
nize the TAA and human constant domains of heavy and
light chains derived from the human IgG1 isotype
[66,67].
The rationale behind this construction was the decrease
in immunogenicity of the antibody, potentially allowing
multiple administrations.
Use of unlabeled antibody cG250
Unlabeled G250 antibody facilitates antibody-dependent
cellular cytotoxicity (ADCC) of G250-antigen expressing
cells, which leads to induction of lysis of these cells[66].
This finding led to a study where 36 patients with meta-
static ccRCC received 50mg cG250 weekly for 12 weeks.
No drug-related grade 34 toxicity occurred during this
trial[68]. Development of human anti chimeric antibody
(HACA) was low and not clinically significant. Before
treatment, 80% of patients were progressive. After treat-
ment, 11 patients had stable disease and during follow-up
one complete and one partial response were seen. The
median survival of 15 months suggested that G250 may
be able to immunomodulate the natural course of meta-
static RCC[69]. Based on these results, an adjuvant phase
III trial has been initiated in high-risk ccRCC patients
who are nephrectomized and have no known metastases,
using this treatment regimen.
Since the 1990s, high-dose bolus interleukin-2 (IL-2)
has been established as a first-line therapy for metastatic
RCC. IL-2 is a T-cell growth factor that is thought to play
a critical role in T-cell dependent immune responses.
High-dose bolus IL-2 as therapy in metastatic RCC has
had varying success, with responses in up to 15% of
patients[70]. It was hypothesized that the immunological
specificity of lymphokine-activated killer cells of patients
receiving IL-2 therapy may be enhanced through the co-
administration of cG250[66]. Vice versa, co-administra-
tion of IL-2 can enhance the therapeutic efficacy of
G250[7173].
In a phase II trial 35 patients with progressive ccRCC
received weekly i.v. infusions of 50mg G250 and daily
s.c. low-dose IL-2, for 11 weeks. When patients
responded or disease stabilized, therapy was continued
for another 6 weeks. Treatment was safe and well toler-
ated. After 16 weeks, 1 partial response was noted and
11 patients had stabilized. These 12 patients continued
treatment. This resulted in 1 partial response and 7
patients retained stable disease. Mean survival was
24 months in this trial, compared to 16.3 months
median survival with high-dose IL-2 therapy[70], which
also has toxic side effects. The authors considered it
unlikely that the increased survival was due to the low-
dose IL-2, using a six-fold decrease of normal IL-2 dose
used to induce clinical efficacy. They considered it rather
a synergic effect of G250 and IL-2[74].
Studies with cG250 labeled with
indium, iodine and lutetium
After cG250 became available, the pharmacokinetics,
biodistribution, imaging characteristics and dosimetry
of this new radiolabeled targeting vehicle was studied
in a protein dose escalation study identical to murine
G250. Sixteen presurgical RCC patients received increas-
ing doses of cG250 between 2 and 50mg labeled with
131I, given i.v. a week before they underwent nephrect-
omy. Highest tumor uptake was observed in the patients
that received 5 and 10mg [131I]mG250, with focal tumor
uptake as high as 0.52% ID/g. At higher protein doses,
focal tumor uptake did not exceed 0.017% ID/g. This
suggested that antigen-saturation could have occurred
at protein doses exceeding 10mg. Excellent images of
G250-antigen positive tumors were obtained, with visual-
ization of tumor lesions and metastases, seen earlier on
CT or X-ray. No previously unknown lesions were visua-
lized. Dosimetric analysis showed a high radiation-
absorbed dose to primary tumors as well as metastases
(up to 1.9 cGy/MBq to primary tumor). Up to 20 weeks
post-injection, human anti chimeric antibody (HACA)
responses were seen in two patients, but titers were con-
sidered low and clinically irrelevant[75]. Reducing the
immunogenic properties of the antibody opened the
possibility of multiple treatments. These results justified
further investigation on the use of cG250 as a radioim-
munotherapeutic agent.
The MTD of [131I]cG250 in metastatic RCC was
determined in a phase I radioactivity dose escalation
Radiolabeled antibodies in renal cell carcinoma 183
trial in patients with progressive metastatic RCC at study
entry. Twelve patients received 5mg of cG250 labeled
with 185 MBq 131I (scout dose). When accumulation
of antibody was seen in any tumor site, patients received
escalating radioactivity-doses of [131I]cG250. In contrast
to the trials performed with murine G250, no hepatic
toxicity was seen. This was believed to be the result of
saturation of the hepatic compartment by the diagnostic
scout dose of [131I]cG250. Besides mild nausea without
vomiting and transient fatigue (both grade 1 CTC), no
other non-hematological side effects occurred. The MTD
was observed to be 2220 MBq/m2, with hematological
toxicity as the dose-limiting factor. Of the 8 patients
receiving treatment, 1 showed stable disease and 1 had
a partial response[76].
In subsequent studies two strategies were tested to opti-
mize targeting of metastatic ccRCC with RIT. These were
fractionation of the dose and two sequential high-dose
treatments.
Fractionation of the dose was done in a phase I study
by Divgi et al.[77]. In this study, patients received 1110
MBq of [131I]cG250 and whole-body activity was mea-
sured after 23 days. Then, another administration of
[131I]cG250 was given to again top up the radioactivity
in the body to 1110 MBq. This was continued until a
whole-body absorbed dose of 0.50Gy was reached.
Patients without disease progression were retreated
after recovery from hematological toxicity. In subsequent
cohorts, the whole-body absorbed dose was increased by
0.25Gy. A total of 15 patients were included in the trial.
HACA development was measured in two patients, alter-
ing pharmacokinetics and excluding them from further
treatment. Dose-limiting toxicity was again hematopoie-
tic, with the MTD at 0.75Gy as whole-body absorbed
dose. Four patients received multiple fractionated
doses. Seven patients stabilized, but no major clinical
responses were seen. This trial therefore provided no
evidence of a potential benefit of fractionation of RIT
doses in treating ccRCC.
The MTD found in the activity dose-escalation study
by Steffens et al. (2220 MBq/m2), combined with the
properties of cG250 allowing multiple administrations,
led to a study where two sequential high doses of
[131I]cG250 treatment were given. Patients had progres-
sive metastatic ccRCC at study entry. Patients received
2220 MBq/m2 [131I]cG250. Three months later, rapid
clearance of the mAb by HACA development was
excluded by imaging of a scout dose of 185 MBq
[131I]cG250. When tumor targeting was seen again, the
second high-dose injection [131I]cG250 was given. MTD
of the second RIT proved to be again due to hematolo-
gical toxicity and was set at 1665 MBq/m2, being 75% of
the MTD of the first infusion). Subsequently, 15 patients
were treated at this dose level to evaluate tumor response.
In total, 29 patients entered the study, 11 were excluded
due to grade 4 hematological toxicity after the first RIT
(n¼3), palliative treatment (n¼2), rapid progressive
disease (n¼2) or HACA development (n¼4). Of the
18 patients evaluated (3 not receiving the second RIT
at MTD), 5 patients had stabilization of their disease,
lasting 312 months. No partial or complete responses
were seen. There proved to be an inverse correlation
between the size of metastases and radiation absorbed
dose. Therapeutic radiation doses (more than
50Gy)[78] were only guided to the lesions smaller than
5 g. The authors concluded that RIT in RCC patients
could best be given in the setting of small volume disease
or as adjuvant therapy[79].
Various radionuclides in targeting ccRCC with cG250
have been under investigation. First, the targeting cap-
abilities of [111In]cG250 have been compared to those
of [131I]cG250. In nude mice-human tumor models, supe-
rior targeting of 111In over 131I had been shown[80,81].
As part of the cG250 antibody-antigen complex is inter-
nalized, intracellular [131I]cG250 is metabolized and rap-
idly excreted by the tumor cell. Metallic radionuclides,
such as 111In, 90Y and 177Lu, are trapped in the lyso-
somes and residualize after internalization of the mAb-
antigen complex by the target cells[8285]. To investigate
whether this phenomenon may also occur in humans,
five patients with metastatic RCC were i.v. injected
with 185 MBq of [111In]DTPA-cG250 on day 0 and
185 MBq of [131I]cG250 on day 4. Gamma images
were made directly and on day 4 after both injections
and compared (Fig. 1). [111In]DTPA-cG250 images
revealed more lesions than [131I]cG250 (47 vs. 30) and
quantitative analysis showed higher accumulation of
[111In]DTPA-cG250 in 20 of 25 lesions measured in
terms of %ID/g[52].
The therapeutic properties of cG250 labeled with four
radionuclides have been tested in nude mice with human
RCC xenografts. The four radionuclides under investiga-
tion were 90Y and 177Lu (both residualizing), and 131I
and 186Re (both non-residualizing). After determining the
MTD for each radionuclide conjugated to cG250 in
mice, an RIT experiment was done comparing tumor
growth and survival after treatment with each radiola-
beled cG250 preparation. Tumor growth was delayed
most effectively by 177Lu, followed by 90Y and 186Re
and least by 131I (185, 125, 90 and 25 days, respectively).
The best median survival was observed for 177Lu
(300 days), with the control group having a median sur-
vival of less than 150 days. The residualizing radionu-
clides 177Lu and 90Y led to higher radiation doses to
the tumor. These radionuclides should be considered
better candidates for RIT with cG250 than 131I[86].
Based on these preclinical and clinical data (Table 2),
an ongoing phase I/II [177Lu]DOTA-cG250 dose escala-
tion RIT study in progressive, metastatic RCC patients
was designed. Patients in whom cG250 targeting of RCC
metastases is observed are treated with up to three cycles
of [177Lu]DOTA-cG250 to determine MTD. So far,
minor responses have been noted at the lower dose
levels and dose escalation is ongoing.
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Future strategies to improve clinical efficacy of cG250
could be: (1) tumor pretargeting; (2) high dose RIT with
bone marrow support or transplant or (3) use of high
linear energy transfer (LET) particles emitting
radionuclides. In pretarging RIT, administration of the
mAb is separated from the injection of the radionuclide.
This allows the unlabeled mAb to bind to the tumor
as well as to clear from circulation and normal organs.
Figure 1 (a) [111In]cG250 immunoscintigram of a patient with metastatic ccRCC, acquired 6 days after injection of
185 MBq of [111In]cG250. Black arrows mark the RCC lesions. Green arrows mark a lesion not seen on
the fluorodeoxyglucose (FDG)-positron emission tomography (PET)-computed tomography(CT) images shown in
(b). Red arrows indicate the injection standard. The anterior image is shown in the left panel, the posterior image is
shown in the right panel. (b) PET-CT scan of the same patient acquired after injection of 250 MBq of [18F]FDG.
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The radionuclide is administered in a second injection as
a rapidly clearing agent with high affinity to the pre-
viously administered mAb. Affinity of the radionuclide
binding to the mAb may be achieved through, e.g. an
avidin-biotin complex or with bispecific mAbs
(bsmAbs). Biotinylated mAb and radionuclides can be
coupled through an extremely avid interaction with
avidin (for review see Boerman et al.[87] and
Goldenberg et al.[88]). For cG250, a bsmAb (cG250 X
DTIn-1) was produced and pretargeting experiments
in nude mice with RCC xenografts targeted with
111In-labeled bivalent peptide showed excellent tumor
targeting[89,90]. To date, however, this approach has not
been tested clinically for cG250.
Autologous marrow transplantation or peripheral
blood stem cell reinfusion has been investigated as a
means to overcome bone marrow toxicity in RIT, thereby
allowing administration of activity doses more than twice
as high as without any bone marrow support[91,92].
The use of LET (alpha) particle emitting radionuclides
has the advantage of high cytotoxic potency, combined
with a low range and thus not reaching most normal
tissue surrounding the tumor. However, most alpha-
emitters have a half-life of less than 1 h, which is hardly
compatible with mAbs targeting tumors.
G250 has demonstrated excellent targeting abilities in
ccRCC patients. Nevertheless, to date clinical impact of
RIT for treatment of ccRCC has been minimal. It
remains to be established whether the use of more pow-
erful radionuclides can lead to alteration of the clinical
course of metastatic ccRCC. Second, G250 may be more
valuable in an adjuvant setting and/or as a diagnostic
means. Finally, with the advent of new treatment
possibilities for RCC such as angiogenesis inhibitors,
combination treatment with G250 RIT and these new
substances may play a role in more effective management
of ccRCC.
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